BE2022C501I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2022C501I2 BE2022C501I2 BE2022C501C BE2022C501C BE2022C501I2 BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2 BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003020854 | 2003-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2022C501I2 true BE2022C501I2 (fr) | 2023-03-07 |
Family
ID=32820637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2022C501C BE2022C501I2 (fr) | 2003-01-29 | 2022-01-03 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US7300935B2 (fr) |
| EP (1) | EP1591446B1 (fr) |
| KR (1) | KR101074462B1 (fr) |
| CN (2) | CN100360538C (fr) |
| AU (1) | AU2004207706B2 (fr) |
| BE (1) | BE2022C501I2 (fr) |
| BR (1) | BRPI0407082C1 (fr) |
| CA (1) | CA2514407C (fr) |
| CO (1) | CO5590921A2 (fr) |
| CY (1) | CY1114008T1 (fr) |
| DK (1) | DK1591446T3 (fr) |
| ES (1) | ES2410814T3 (fr) |
| FR (1) | FR21C1056I2 (fr) |
| HK (1) | HK1084665A1 (fr) |
| HU (1) | HUS2100052I1 (fr) |
| IL (1) | IL169869A (fr) |
| LT (1) | LTC1591446I2 (fr) |
| MX (1) | MXPA05007990A (fr) |
| NL (1) | NL301158I2 (fr) |
| NO (2) | NO331981B1 (fr) |
| NZ (1) | NZ541772A (fr) |
| PL (1) | PL214756B1 (fr) |
| PT (1) | PT1591446E (fr) |
| RU (1) | RU2331648C2 (fr) |
| SI (1) | SI1591446T1 (fr) |
| WO (1) | WO2004067535A1 (fr) |
| ZA (1) | ZA200506611B (fr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20090048273A1 (en) | 2005-07-22 | 2009-02-19 | Takeda Pharmaceutical Company Limited | Premature ovulation preventive agent |
| US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
| US20110172249A1 (en) * | 2008-09-03 | 2011-07-14 | Takeda Pharmaceutical Company Limted | Method for improving absorbability of preparation, and preparation having improved absorbability |
| JP5452617B2 (ja) | 2009-01-08 | 2014-03-26 | キュリス，インコーポレイテッド | 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター |
| US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
| US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
| ES2733128T3 (es) | 2011-04-01 | 2019-11-27 | Curis Inc | Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc |
| CN104105485B (zh) * | 2011-11-11 | 2017-04-12 | 吉利德阿波罗公司 | Acc抑制剂和其用途 |
| EP2900675B1 (fr) | 2012-09-28 | 2019-03-06 | Takeda Pharmaceutical Company Limited | Procédé de production d'un dérivé de thiénopyrimidine |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| EP2881391A1 (fr) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Dérivés de carbocycle spiroindoline et leurs compositions pharmaceutiques |
| MX2017010945A (es) * | 2015-02-26 | 2018-07-06 | Takeda Pharmaceuticals Co | Preparacion solida. |
| ES2882255T3 (es) | 2015-07-01 | 2021-12-01 | California Inst Of Techn | Sistemas de administración basados en polímeros de ácido múcico catiónicos |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| CN108349994B (zh) | 2015-11-25 | 2021-06-22 | 吉利德阿波罗公司 | ***acc抑制剂及其用途 |
| ES2855348T3 (es) | 2015-11-25 | 2021-09-23 | Gilead Apollo Llc | Inhibidores de éster ACC y usos de los mismos |
| SI3380480T1 (sl) | 2015-11-25 | 2023-04-28 | Gilead Apollo, Llc | Pirazolni inhibitorji ACC in uporabe le-teh |
| EP3379933B1 (fr) | 2015-11-25 | 2023-02-15 | Gilead Apollo, LLC | Composition fongicide contenant des dérivés de 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine |
| RU2610281C1 (ru) * | 2016-02-26 | 2017-02-08 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) | Способ получения 2-фтор-3-метилбут-2-ениламина или его гидрохлорида (Варианты) |
| CA3220447A1 (fr) | 2016-03-02 | 2017-09-08 | Gilead Apollo, Llc | Formes solides d'un inhibiteur de thienopyrimidinedione acc et leurs procedes de production |
| AU2017334035B2 (en) | 2016-09-30 | 2022-11-24 | Myovant Sciences Gmbh | Treatment of prostate cancer |
| HUE059101T2 (hu) | 2016-09-30 | 2022-10-28 | Myovant Sciences Gmbh | Eljárások uterinális fibroidok és endometriózis kezelésére |
| PL3600309T3 (pl) | 2017-03-28 | 2022-11-07 | Gilead Sciences, Inc. | Skojarzenia terapeutyczne do leczenia chorób wątroby |
| EP3634418A1 (fr) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose |
| EP3765464A1 (fr) * | 2018-03-14 | 2021-01-20 | Teva Pharmaceuticals USA, Inc. | Formes à l'état solide de relugolix |
| BR112021004371A2 (pt) | 2018-09-11 | 2021-05-25 | Curis Inc. | terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco |
| MA54058A (fr) | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| JP7459086B2 (ja) | 2018-11-07 | 2024-04-01 | キッセイ薬品工業株式会社 | エストロゲン依存性障害の治療のための組成物及び方法 |
| EP3666776A1 (fr) * | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate d'un antagoniste de récepteur d'hormone libérant du gonadolibérine |
| EP3969455A4 (fr) * | 2019-05-15 | 2023-07-05 | Dr. Reddy's Laboratories Limited | Formes amorphes et cristallines du rélugolix |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| CN111943960B (zh) * | 2019-07-29 | 2022-02-15 | 广东东阳光药业有限公司 | 取代的嘧啶二酮类化合物及其用途 |
| CA3145993A1 (fr) * | 2019-08-02 | 2021-02-11 | Johnson Matthey Public Limited Company | Formes a l'etat solide de relugolix |
| CN112321602A (zh) * | 2019-08-05 | 2021-02-05 | 苏州鹏旭医药科技有限公司 | 一种瑞卢戈利药物中间体的制备方法 |
| WO2021023876A1 (fr) | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Antagonistes de gnrh pour le traitement de troubles dépendant des œstrogènes |
| CN114466665A (zh) | 2019-08-08 | 2022-05-10 | 奥布赛瓦股份公司 | 用于治疗***依赖性病症的组合物和方法 |
| CN112390812A (zh) * | 2019-08-14 | 2021-02-23 | 苏州鹏旭医药科技有限公司 | 瑞卢戈利化合物的晶型和无定型固体及其制备方法 |
| CN112771052B (zh) * | 2019-08-21 | 2023-04-07 | 深圳仁泰医药科技有限公司 | 促性腺素释放激素拮抗剂的晶型及其制备方法和用途 |
| WO2021069700A1 (fr) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Formes cristallines solvatées de n-(4-(1-(2,6-difluorobenzyle)-5- ((diméthylamino)méthyle)-3-(6-méthoxy-3-pyridazinyle)-2,4-dioxo -1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidine-6-yl) phényle)-n'-méthoxyurée |
| CN115279769A (zh) * | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| CN112745304A (zh) * | 2019-10-29 | 2021-05-04 | 上海度德医药科技有限公司 | 一种Relugolix的制备方法及中间体化合物 |
| CN113444105A (zh) * | 2020-03-27 | 2021-09-28 | 南京海润医药有限公司 | 一种Relugolix的制备方法 |
| CN111333633B (zh) * | 2020-04-01 | 2023-10-20 | 江西科睿药业有限公司 | 一种瑞卢戈利的中间体化合物及其制备方法和用途 |
| CN111574534B (zh) * | 2020-05-25 | 2021-06-04 | 东莞市东阳光新药研发有限公司 | 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途 |
| JP2023528014A (ja) | 2020-05-29 | 2023-07-03 | ミオバント サイエンシズ ゲーエムベーハー | ゴナドトロピン放出ホルモンアンタゴニストの組合せ固体経口製剤 |
| CN111875614B (zh) * | 2020-07-03 | 2022-04-29 | 东莞市东阳光新药研发有限公司 | 杂环基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途 |
| CN111793078B (zh) * | 2020-07-03 | 2022-02-01 | 东莞市东阳光新药研发有限公司 | 双环含氮杂芳基取代的嘧啶二酮类化合物及其用途 |
| CN111925379B (zh) * | 2020-07-31 | 2022-02-15 | 广东东阳光药业有限公司 | 含氮杂芳基取代的嘧啶二酮类化合物及其用途 |
| CN111909168B (zh) * | 2020-07-31 | 2022-02-01 | 广东东阳光药业有限公司 | 含氮杂环基取代的嘧啶二酮类化合物及其用途 |
| CN113754679B (zh) * | 2020-09-09 | 2023-04-07 | 广东东阳光药业有限公司 | 取代的嘧啶二酮类化合物及其用途 |
| CN112047957B (zh) * | 2020-09-09 | 2022-02-01 | 广东东阳光药业有限公司 | 取代的嘧啶二酮类化合物及其用途 |
| CN112142757B (zh) * | 2020-09-29 | 2022-02-15 | 广东东阳光药业有限公司 | 五元含氮杂芳基取代的嘧啶二酮类化合物及其用途 |
| WO2022101303A1 (fr) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Méthodes d'administration du rélugolix |
| CN112552312B (zh) * | 2020-12-07 | 2022-08-05 | 杭州科巢生物科技有限公司 | 一种瑞卢戈利或其盐的合成方法 |
| CN113620972A (zh) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | 瑞卢戈利新晶型及其制备方法 |
| CN114907370B (zh) | 2021-02-10 | 2023-11-03 | 奥锐特药业(天津)有限公司 | 高纯度的噻吩并嘧啶化合物及其制备方法 |
| CN115073491A (zh) * | 2021-03-12 | 2022-09-20 | 上海医药工业研究院 | 一种瑞卢戈利中间体、其制备方法及其应用 |
| WO2022214645A1 (fr) | 2021-04-09 | 2022-10-13 | Farmhispania Group, S.L. | Procédés et intermédiaires pour la préparation de rélugolix |
| CN113135934A (zh) * | 2021-04-28 | 2021-07-20 | 北京海美源医药科技有限公司 | 用于制备瑞卢戈利的中间体化合物及其制备方法和瑞卢戈利的制备方法 |
| CN115260211B (zh) * | 2021-04-29 | 2024-02-06 | 长春金赛药业有限责任公司 | 含噻吩稠环类衍生物、药物组合物及其制备方法和应用 |
| WO2023066941A1 (fr) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Forme cristalline d'un solvate d'éthanol de n-(4-(1-(2,6-difluorobenzyle)-5-((diméthylamino)méthyle)-3-(6-méthoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl)phényle)-n'-méthoxyurée |
| WO2023072284A1 (fr) * | 2021-11-01 | 2023-05-04 | 山东绿叶制药有限公司 | Antagoniste de l'hormone de libération de la gonadotropine, son procédé de préparation et son utilisation |
| CN114230576A (zh) * | 2021-12-21 | 2022-03-25 | 伊诺药物研究(南京)有限公司 | 一种瑞卢戈利的制备方法 |
| CN114989134B (zh) * | 2022-07-14 | 2023-11-14 | 江西同和药业股份有限公司 | 一种噻吩类化合物及其制备方法与应用 |
| CN115417883A (zh) * | 2022-09-16 | 2022-12-02 | 浙江科聚生物医药有限公司 | 一种瑞卢戈利的晶型及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048863A (en) | 1994-04-19 | 2000-04-11 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use |
| UY23948A1 (es) | 1995-02-08 | 2001-10-25 | Takeda Chemical Industries Ltd | Derivados de anillos condensados de tiofeno su producción y uso. |
| US6297379B1 (en) * | 1999-03-24 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| JP2001316391A (ja) * | 2000-02-29 | 2001-11-13 | Takeda Chem Ind Ltd | チエノピリミジン誘導体の製造法 |
| CA2401379A1 (fr) | 2000-02-29 | 2001-09-07 | Junichi Kawakami | Procedes de production de derives de thienopyramidine |
| US20030134863A1 (en) | 2000-04-13 | 2003-07-17 | Shuichi Furuya | Preventives/remedies for alzheimer's disease |
| JP2001354588A (ja) * | 2000-04-13 | 2001-12-25 | Takeda Chem Ind Ltd | アルツハイマー病予防・治療剤 |
| JP2002068982A (ja) * | 2000-06-14 | 2002-03-08 | Takeda Chem Ind Ltd | 徐放性組成物 |
| WO2001095940A1 (fr) | 2000-06-14 | 2001-12-20 | Takeda Chemical Industries, Ltd. | Compositions a liberation continue |
| JP2002080397A (ja) * | 2000-07-05 | 2002-03-19 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患の治療用医薬製剤 |
| CA2412899C (fr) | 2000-07-05 | 2010-11-09 | Takeda Chemical Industries, Ltd. | Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles |
| JP2002167327A (ja) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | 固形製剤 |
| WO2002024230A1 (fr) | 2000-09-22 | 2002-03-28 | Takeda Chemical Industries, Ltd. | Preparations solides |
| WO2002043766A1 (fr) * | 2000-11-29 | 2002-06-06 | Takeda Chemical Industries, Ltd. | Compositions medicinales et leur procede de preparation |
| AU2002221139A1 (en) | 2000-12-15 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
| EP1370562A1 (fr) * | 2001-02-14 | 2003-12-17 | Warner-Lambert Company LLC | Derives de thieno'2,3-d pyrimidinone utilises comme inhibiteurs de metalloproteinases matricielles |
| JP5072166B2 (ja) * | 2002-01-30 | 2012-11-14 | 武田薬品工業株式会社 | チエノピリミジン化合物、その製造法および用途 |
| WO2003064429A1 (fr) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, procedes de fabrication et d'utilisation correspondants |
| WO2003075958A1 (fr) | 2002-03-11 | 2003-09-18 | Takeda Chemical Industries, Ltd. | Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle |
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| JP2004002377A (ja) * | 2002-04-12 | 2004-01-08 | Takeda Chem Ind Ltd | ホットフラッシュ予防・治療剤 |
| CA2481391A1 (fr) | 2002-04-12 | 2003-10-23 | Takeda Pharmaceutical Company Limited | Agents pour prevenir/traiter les bouffees de chaleur |
-
2004
- 2004-01-28 KR KR1020057014100A patent/KR101074462B1/ko active IP Right Grant
- 2004-01-28 EP EP04705950A patent/EP1591446B1/fr not_active Expired - Lifetime
- 2004-01-28 CA CA2514407A patent/CA2514407C/fr not_active Expired - Fee Related
- 2004-01-28 PL PL378002A patent/PL214756B1/pl unknown
- 2004-01-28 RU RU2005127052/04A patent/RU2331648C2/ru active
- 2004-01-28 CN CNB2004800087989A patent/CN100360538C/zh not_active Expired - Lifetime
- 2004-01-28 BR BRPI0407082A patent/BRPI0407082C1/pt active IP Right Grant
- 2004-01-28 DK DK04705950.6T patent/DK1591446T3/da active
- 2004-01-28 WO PCT/JP2004/000741 patent/WO2004067535A1/fr not_active Application Discontinuation
- 2004-01-28 MX MXPA05007990A patent/MXPA05007990A/es active IP Right Grant
- 2004-01-28 PT PT47059506T patent/PT1591446E/pt unknown
- 2004-01-28 NZ NZ541772A patent/NZ541772A/en not_active IP Right Cessation
- 2004-01-28 CN CNA2007101869688A patent/CN101153042A/zh active Pending
- 2004-01-28 SI SI200432035T patent/SI1591446T1/sl unknown
- 2004-01-28 US US10/544,069 patent/US7300935B2/en not_active Expired - Lifetime
- 2004-01-28 AU AU2004207706A patent/AU2004207706B2/en active Active
- 2004-01-28 ES ES04705950T patent/ES2410814T3/es not_active Expired - Lifetime
- 2004-01-28 ZA ZA200506611A patent/ZA200506611B/en unknown
-
2005
- 2005-07-25 IL IL169869A patent/IL169869A/en active IP Right Grant
- 2005-08-25 CO CO05084855A patent/CO5590921A2/es unknown
- 2005-08-25 NO NO20053974A patent/NO331981B1/no not_active IP Right Cessation
-
2006
- 2006-04-24 HK HK06104843.5A patent/HK1084665A1/xx not_active IP Right Cessation
-
2007
- 2007-08-31 US US11/848,939 patent/US8058280B2/en active Active
-
2011
- 2011-09-23 US US13/242,541 patent/US8735401B2/en not_active Expired - Lifetime
-
2013
- 2013-05-29 CY CY20131100419T patent/CY1114008T1/el unknown
-
2014
- 2014-04-11 US US14/251,119 patent/US9346822B2/en not_active Expired - Lifetime
-
2021
- 2021-11-19 FR FR21C1056C patent/FR21C1056I2/fr active Active
- 2021-11-19 HU HUS2100052C patent/HUS2100052I1/hu unknown
- 2021-11-24 LT LTPA2021529C patent/LTC1591446I2/lt unknown
- 2021-12-16 NO NO2021052C patent/NO2021052I1/no unknown
- 2021-12-31 NL NL301158C patent/NL301158I2/nl unknown
-
2022
- 2022-01-03 BE BE2022C501C patent/BE2022C501I2/fr unknown